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Abstract
Purpose: The aim of the study was to compare
68Ga-chloride with 2-[
18F]fluoro-2-deoxy-D-
glucose (FDG) for the imaging of pancreatic xenografts.
Procedures: Rats with subcutaneous human pancreatic adenocarcinoma xenografts were
evaluated in vivo by dynamic positron emission tomography (PET) and ex vivo by measuring
radioactivity of excised tissues and by digital autoradiography of tumor cryosections.
Results: Both tracers were capable of delineating all subcutaneous tumors from surrounding
tissues by PET. The standardized uptake values of tumors by PET were 0.9±0.3 (mean±SD) for
68Ga-chloride (n=13) and 1.8±1.2 for FDG (n=11). Ex vivo studies showed tumor-to-muscle
ratio of 4.0±0.3 for
68Ga-chloride (n=4) and 7.9±3.2 for FDG (n=4).
Conclusions:
68Ga-chloride delineated subcutaneously implanted pancreatic adenocarcinoma
xenografts by PET, but the uptake was lower than FDG. Further studies to clarify the value of
68Ga-chloride for PET imaging of tumors are warranted.
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Introduction
G
allium-67 citrate (
67Ga; T1/2=78 h) has been used as
an imaging agent in single-photon emission computed
tomography (SPECT) for decades for the purpose of
detecting certain tumors and infection/inflammation, in spite
of its disadvantages resulting mainly from such unfavorable
physical characteristics as high radiation exposure and long
examination time. The first tumor uptake studies with a
positron-emitting gallium-68 (
68Ga; T1/2=68 min) were
performed in the 1960s [1, 2]. For a long period of time,
68Ga was almost forgotten, but during the last years, it has
gone through a renaissance.
68Ga has been applied for the
labeling of peptides and oligonucleotides with the macro-
cyclic chelating agent 1,4,7,10-tetraazacyclododecane-N,N′,
N″,N‴-tetraacetic acid (DOTA) in order to target tumors by
positron emission tomography (PET) [3, 4]. Some
68Ga-
labeled tumor targeting radiopharmaceuticals, e.g.,
68Ga-
DOTATOC,
68Ga-DOTANOC, and
68Ga-DOTA-Ianreotide
binding to somatostatin receptors,
68Ga-DOTA-bombesin
binding to bombesin receptors, and
68Ga-DOTA-D-Glu-
gastrin binding to gastrin-releasing peptide receptors, have
been reported to be potential imaging agents in clinical
studies [5, 6]. Preclinical evaluation of interesting
68Ga-
labeled biomolecules, e.g.,
68Ga-deferoxamine-folate and
68Ga-DOTA-hEGF, has also been reported [7, 8].
Significance: This is the first study to evaluate
68Ga-chloride for PET
imaging of pancreatic xenografts in comparison with FDG.
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18F]Fluoro-2-deoxy-D-glucose (FDG) is the most widely
used PET imaging agent. FDG is a glucose analog that reflects
the level of glucose metabolism. Glucose consumption is
increased intumorsbecause of rapid cellproliferation.Glucose
and FDG uses GLUT-1 and GLUT-3 cell surface transporters,
which are overexpressed in cancercells [9]. FDG, like glucose,
is phosphorylated by hexokinases (particularly hexokinase II)
into 2-[
18F]fluoro-2-deoxy-D-glucose 6-phosphate (FDG 6-P).
Subsequently, FDG 6-P is trapped inside the cell because it is
not metabolized any further.
Very recently, we have been able to establish a relationship
between the
68Ga-chloride uptake with PET at the site of local
bone infection and underlying structural changes determined
with peripheral quantitative computed tomography [10]. In
addition, when using
68Ga-chloride as a control in our
68Ga-
oligonucleotidestudies,wenoticeduptakeintumorsduring2h
PET imaging [4]. The purpose of this study was to prelimi-
narily evaluate if gallium-68 (
68Ga) could be used for PET
imaging of tumors in a similar fashion as
67Ga is used for
SPECT. The advantage of
68Ga-chloride over FDG would be
the fast and simple production, i.e., the cyclotron and labeling-
free production.
68Ga-chloride is readily available at a PET
laboratory. We tested
68Ga-chloride by PET imaging of
experimental tumors in comparison with FDG. The results
were also verified ex vivo. Compared with the use of
67Ga in
SPECT,
68Ga-chloride PET would have the following advan-
tages:betterspatialresolution,highersensitivity,possibilityfor
quantitative assessment of tracer accumulation in tissues, and
lower absorbed radiation dose for the study subject.
Materials and Methods
Preparation of Tracers
68Ga-chloride was eluted with 0.1 M HCl from a
68Ge/
68Ga
generator (Cyclotron Co., Obninsk, Russia). The radioactive elution
peak, monitored online with a positron-sensitive photodiode
detector (Hamamatsu S5591, Hamamatsu Photonics K.K. Solid
State Division, Hamatsu City, Japan), was collected, and the
68Ga-
chloride was neutralized with 1.0 M NaOH. FDG was prepared as
described earlier [11].
Animal Model
The human pancreatic ductal adenocarcinoma cell line, BxPC-3, was
purchased from American Type Culture Collection (Rockville, MD,
USA). The cells were grown in RPMI 1640 culture medium
supplemented (10%) with heat-inactivated fetal bovine serum, 2 mM
L-glutamine, 100 U/mL penicillin, and streptomycin (100µg/mL) in a
humidified atmosphere of 5% CO2 at 37°C. The cells were detached
from the culture bottle by trypsin–ethylenediaminetetraacetic acid and
resuspended (5×10
7cells/mL) in medium for implantation.
Twenty-nine athymic male Hsd/RH-rnu/rnu rats were obtained
from Harlan (The Netherlands) at the age of 6 weeks. Tumor cells
(10
7/rat) were injected subcutaneously into the neck, and tumors were
allowed to grow to a size of 1 cm in diameter. All animal studies had
been approved by the Lab-Animal Care & Use Committee of the
University of Turku.
PET Imaging
To detect the tumor uptake of tracers and to quantify their organ
distribution and kinetics, 2 h dynamic PET imaging was performed.
Nineteen rats with BxPC-3 xenografts (weight 336±50 g) were
anesthetized intraperitoneally with sodium pentobarbital (60 mg/kg;
Mebunat, Orion, Finland) or with a mixture of fentanyl citrate plus
fluanisone (0.25 and 8.0 mg/kg, respectively; Hypnorm
® =f e n t a n y l
citrate0.315mg/mLandfluanisone10mg/mL,JanssenPharmaceutica,
Beerse, Belgium) and midazolam (4.0 mg/kg; Dormicum 5 mg/mL,
Roche, Espoo, Finland). The rats were placed in the center of the
scanner gantry to obtain the best resolution for small objects and kept
on a warm pallet during the imaging procedure. PET imaging was
performed either with Advance scanner (GE Medical Systems,
Milwaukee, WI, USA) or with HRRT camera (Siemens Medical
Solutions, Knoxville, TN, USA) [12, 13].
After transmission scan for attenuation correction, a tracer was
injected directly as a bolus intravenously via a tail vein. PET imaging
startedatthetimeofinjection.Themean±SDdosewas16±3MBqfor
68Ga-chloride (n=13) and 16±9 MBq for FDG (n=11). Prior to tracer
injection, rats fasted for at least 2 h. Of a total of 19 rats, five were
imaged with both tracers on subsequent days. The acquisition times
were 5×60 and 23×300 s, with the total imaging duration being
120 min.
PET data were iteratively reconstructed with the ordered-subsets
expectation maximization (OS-EM) algorithm. All PET images were
reviewed on computer screen in the transaxial, coronal, and sagittal
planes along with maximum-intensity-projection images. Two
reviewers aware of subcutaneously implanted tumor xenografts in
the neck area independently evaluated tracer uptake both visually and
semiquantitatively. The radiotracer uptake in the tumor was visually
compared to the surrounding tissue (skin, fat, and muscle) uptake
as negative, less-than-surrounding tissue uptake or equivalent-to-
surrounding tissue uptake, and positive, uptake which is higher than
the surrounding tissue uptake. In case of discrepancies between the
two reviewers, a consensus was reached in a joint reading session.
Semiquantitative analysis was performed by drawing a standardized
circular region of interest (ROI) to the tumor (ROI Ø 5 mm), heart
(ROI Ø 6 mm), kidney (ROI Ø 4 mm), liver (ROI Ø 6 mm), and
urinary bladder (ROI Ø 4 mm) areas. The heart ROI was drawn to
cover the whole heart including both myocardium and the blood pool
radioactivity. The average radioactivity concentration in a ROI
(kiloBecquerels per milliliter) was used for further analyses. The
tracer uptake wasreported asmean standardizeduptake values (SUV),
which was calculated as the radioactivity of the ROI divided by the
injected dose per animal body weight. Biokinetic/time–activity curves
(TAC), representing the relative radioactivity concentration in the
organ of interest (SUV) vs. time after injection, were determined
accordingly. TACs were decay corrected to the time of injection.
Ex Vivo Measurements
T h eu p t a k eo f
68Ga-chloride and FDG in tumors was studied ex vivo in
tumor-bearinganimals.Eight rats(weight 280±69g) wereanesthetized
with a mixture of Hypnorm–Dormicum, as described above and
intravenously administered with 12±3 MBq of
68Ga-chloride (n=4)or
15±3 MBq of FDG (n=4). Prior to tracer injection, rats fasted for at
least 2 h. Ninety minutes after tracer distribution, a blood sample was
obtained via intracardiac puncture, and the animals were killed by
intracardiac administration of sodium pentobarbital (Mebunat
®,O r i o n ,
Finland). The time point for ex vivo measurements was based on our
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skin were excised, weighed, and measured for total radioactivity in an
automated gamma counter (1480 Wizard 3″ Gamma Counter; EG & G
Wallac, Turku, Finland) cross-calibrated with a dose calibrator (VDC-
202, Veenstra Instruments, Joure, The Netherlands) and PET cameras.
The tail was also measured for radioactive content to determine the
accuracy of the injections. The radioactivity concentration was decay
corrected to the time of injection, the radioactivity remaining in the tail
was compensated, and the results were expressed as SUV (organ
radioactivity/organ weight)/(total given radioactivity/rat body weight).
The radioactivity ratios between the target (tumor) and nontarget
(blood, liver, lung, muscle, and skin) organs were also calculated.
Tumor Autoradiography, Histology,
and Immunohistochemical Staining
Tworats(weight224gand213g)wereinjectedwith19MBqof
68Ga-
chloride or 24 MBq of FDG, respectively. After tracer distribution
(90 min), the tumors were excised, frozen in dry ice, and cut with a
cryomicrotome into 10–20-μm sections. Tumor sections were thaw-
mounted onto microscope slides, briefly air dried, and exposed to an
imaging plate (Fujifilm BAS TR, Fuji Photo Film Co, Japan) for two
half-livesofradio-isotope inquestion.Thedistributionofradioactivity
in the sections was digitally scanned using a Fuji BAS-5000 device
(Fuji Tokyo, Japan) with the image resolution of 25μm.
After autoradiography, the same sections were stained with
hematoxylin and eosin (HE) or using an immunohistochemical
method for light microscopy to obtain corresponding histological
information. In addition, some tumor samples were fixed with 4%
formaldehyde, embeddedinparaffin, and cut into10-μm sections, and
thesectionswerestainedwithHE.Forimmunohistochemicalstaining,
DakoCytomation EnVision-system-HRP (K4001, Dako, Glostrup,
Denmark) two-step immunohistochemical technique was used.
After
68Ga-chloride autoradiography, the sections were stained
with mouse antirat CD68 monoclonal antibody (MCA341GA; AbD
Serotec, Oxford, UK; optimal dilution 1:2,000) to examine if the
c
Fig. 1. Coronal PET images of a rat injected with a
68Ga-chloride and b FDG on subsequent days. Tumor formed by
subcutaneously implanted BxPC-3 human pancreatic adenocarcinoma cells is marked with a white arrow. Urinary bladder is
marked with a black arrow. Images (a summation of a 60- to 70-min period after injection) are color-coded according to the
level of radioactivity, from dark blue (the lowest) to hot red (the highest). c The tumor uptake (standardized uptake value, SUV)
of
68Ga-chloride and FDG as a function of time.
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located with 3,3′-diaminobenzidine tetrahydrochloride (Liquid
DAB Substrate, K3468; Dako, Glostrup, Denmark). Finally,
immunohistochemical sections were slightly counterstained with
Mayer's hematoxylin, washed, and mounted.
The digital autoradiographs were combined with digital histo-
logical and immunohistological images using GIMP 2.4.5 (GNU
Image Manipulation Program, authored by Peter Mattis and
Spencer Kimball; http://www.gimp.org/) and Hugin 0.7 beta 3
hugin (Hugin, authored by Andrew Mihal, Pablo d'Angelo, Max
Lyons, Erik Krause, Konstantin Rotkvich, and Christoph Spiel;
http://hugin.sourceforge.net/) softwares. The intratumoral tracer
distribution was reviewed on computer screen by two observers.
Statistical Methods
All the results are expressed as mean±SD. After testing of
normality and variance, an analysis of variance test was applied
to study the significance of differences between the tracers. A t test
was used for the comparison of PET and ex vivo data. A log
transformation because of skeweness was used for all data, except
for comparison of ex vivo measurements. A P value of less than
0.05 was considered statistically significant. Statistical analyses
were conducted using SAS 9.1.3 statistical software (SAS Institute
Inc., Cary, NC, USA).
Results
PET Imaging
Both tracers were capable of delineating all subcutaneous
BxPC-3 tumor xenografts from surrounding tissues by PET
(Fig. 1a, b). Based on 2 h dynamic PET imaging, the peak
radioactivity of
68Ga-chloride in the tumor was reached faster
in comparison to FDG. The uptake of
68Ga-chloride at the site
of tumors showed very fast initial uptake and moderate
decline with a plateau at 10 min after injection. In contrast,
uptake of FDG accumulated slowly and reached a plateau at
60 min (Fig. 1c). According to PET imaging, the tumor
uptake expressed as SUV was 0.9±0.3 for
68Ga-chloride
(n=13)and1.8±1.2forFDG (n=11;Table1).TheFDGSUV
of tumor was significantly higher than that of
68Ga-chloride
(P=0.003; Fig. 2). The results obtained by using GE Advance
scanner were in accordance with those obtained by using
Siemens HRRT camera (P>0.05 for both tracers).
In case of
68Ga-chloride, the excess of radioactivity was
distributed into heart, liver, and urinary bladder. The critical
organs for FDG distribution were heart and urinary bladder
(Fig. 1a, b). The corresponding tissue TACs are shown in
Fig. 3.
Ex Vivo Biodistribution
The results of the ex vivo measurements are presented in
Table 2, and they are in accordance with the results of in vivo
PET imaging (P>0.05; Fig. 2). The tumor SUV was 0.9±0.2
for
68Ga-chloride and 2.2±1.2 for FDG, and the difference was
statistically insignificant (P>0.05).
Target-to-nontarget ratios, i.e., tumor-to-blood, tumor-to-
liver, tumor-to-lung, tumor-to-muscle, and tumor-to-skin
ratios, are presented in Table 2 and Fig. 4. The tumor-to-blood
ratio of
68Ga-chloride was significantly lower compared to
FDG (PG0.0001). Both tracers gave tumor-to-muscle ratios
highenoughtodifferentiatethetumorfromsurroundingtissues
(range 3.7–4.3 with
68Ga-chloride and 5.7–12.6 with FDG).
Table 1. Uptake of
68Ga-chloride and FDG in human pancreatic adeno-
carcinoma xenografts in rats by using two different PET devices, i.e., GE
Advance and Siemens HRRT
68Ga-chloride (n=13) FDG (n=11)
GE Advance Siemens
HRRT
GE Advance Siemens
HRRT
Rat # 1 1.0 1.6
Rat # 2 0.9 1.8
Rat # 3 1.3 4.9
Rat # 4 0.7 0.7
Rat # 5 0.6 1.2
Rat # 6 1.7
Rat # 7 0.7
Rat # 8 0.7
Rat # 9 0.7
Rat # 10 0.7
Rat # 11 1.8
Rat # 12 1.9
Rat # 13 1.3
Rat # 14 0.5
Rat # 15 0.9
Rat # 16 0.6
Rat # 17 0.6
Rat # 18 3.0
Rat # 19 1.5
Mean±SD 0.9±0.4 0.7±0.2 1.7±1.3 2.3±1.0
Mean±SD (all) 0.9±0.3 1.8±1.2
Results are expressed as standardized uptake value
Fig. 2. Standardized uptake values (SUV) at tumor site
calculated from PET and ex vivo biodistribution data.
The results of the ex vivo measurements were in accordance
with the results of in vivo PET imaging. ***PG0.005.
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and Immunohistochemical Staining
Representative digital autoradiographs of
68Ga-chloride and
FDG distribution in the tumor tissue are shown in Fig. 5.
The imaging agents showed different biodistribution within
the tumor. The
68Ga radioactivity was quite homogeneously
distributed, while distribution of FDG was more hetero-
genous.
The histological sections of BxPC-3 tumors showed
mainly homogenous, viable tumor tissue without any major
necrotic areas (Fig. 6).
68Ga-chloride uptake by the tumor
ab
c d
Fig. 3. In vivo biokinetics (amount of radioactivity vs. time after injection) of intravenously administered
68Ga-chloride and FDG
in the rat’s a heart, b liver, c kidney, and d urinary bladder. Radioactivity concentrations are expressed as standardized uptake
values (SUV) vs. time after injection (minute). Mean value of 11 to 13 experiments.
Table 2. Ex vivo biodistribution of intravenously administered
68Ga-chloride and FDG in tumor-bearing rats
Blood Liver Lung Muscle Skin Tumor T/B T/Li T/Lu T/M T/S
68Ga-chloride (n=4)
Rat # 20 2.7 6.7 3.0 0.3 0.5 1.0 0.4 0.2 0.4 4.0 2.2
Rat # 21 2.4 8.6 1.5 0.2 0.5 0.9 0.4 0.1 0.6 3.8 1.8
Rat # 22 2.5 7.1 1.9 0.2 0.7 1.0 0.4 0.1 0.6 4.3 1.5
Rat # 23 3.0 1.1 1.0 0.2 0.5 0.7 0.2 0.7 0.7 3.7 1.5
Mean ± SD 2.7±0.3 5.9±3.3 1.9±0.8 0.2±0.03 0.5±0.1 0.9±0.2 0.3±0.1 0.3±0.3 0.5±0.1 4.0±0.3 1.8±0.4
Range 2.4–3.0 1.1–8.6 1.0–3.0 0.2–0.3 0.5–0.7 0.7–1.0 0.2–0.4 0.1–0.7 0.4–0.7 3.7–4.3 1.5–2.2
FDG (n=4)
Rat # 24 0.5 0.7 2.3 0.4 1.6 3.2 5.8 4.8 1.4 7.2 1.9
Rat # 25 0.8 1.1 2.2 0.5 1.5 3.1 3.6 2.9 1.4 6.0 2.1
Rat # 26 0.4 0.5 1.0 0.3 1.1 1.9 5.1 4.0 1.8 5.7 1.8
Rat # 27 0.1 0.1 0.2 0.04 0.2 0.6 8.8 7.4 3.4 12.6 3.4
Mean ± SD 0.5±0.3 0.6±0.4 1.4±1.0 0.3±0.2 1.1±0.7 2.2±1.2 5.8±2.2 4.8±1.9 2.0±0.9 7.9±3.2 2.3±0.7
Range 0.1–0.8 0.1–1.1 0.2–2.3 0.0–0.5 0.2–1.6 0.6–3.2 3.6–8.8 2.9–7.4 1.4–3.4 5.7–12.6 1.8–3.4
Results are expressed as standardized uptake value
T/B tumor/blood, T/Li tumor/liver, T/Lu tumor/lung, T/M tumor/muscle, T/S tumor/skin
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ical staining with mouse antirat CD68 recognizing rat
macrophages revealed homogenous distribution in the tumor
tissue (Fig. 7).
Discussion
This experimental study was designed to investigate the
feasibility of
68Ga-chloride for PET imaging of tumors by
comparing it with FDG. Although FDG is a widely used
imaging agent in PET and
67Ga-citrate in SPECT, compar-
ison with
68Ga-chloride has not been performed earlier. Our
results revealed that
68Ga-chloride was able to differentiate
experimental tumors from surrounding tissues (Fig. 1). The
tumor uptake of
68Ga-chloride was lower than that of FDG
(Table 1; Fig. 2).
Human pancreatic adenocarcinoma xenograft in rat was
chosen for an experimental tumor model, since imaging and
early diagnosis of pancreatic cancer still remains a challenge
[14, 15]. One problem that hinders early diagnosis is that
only symptomatic patients with suspected malignancy are
PET imaged. PET is not the primary method for diagnosis,
even though it has been reported to be the most accurate one
[15]. Since the production of
68Ga-chloride is cyclotron-free,
68Ga-chloride PET might facilitate the availability of PET in
centers where no cyclotron is available.
Both tested tracers were capable of visualizing subcuta-
neous tumors (Fig. 1). According to dynamic PET imaging,
the tumor uptake of
68Ga-chloride was much faster than the
uptake of FDG. Blood clearance of
68Ga radioactivity
estimated from TAC of heart was slower compared with
FDG (Fig. 3a), which is in accordance to the fact that Ga
3+
binds to transferrin. The slow clearance was seen also as the
low tumor-to-blood ratio of
68Ga-chloride as noticed by ex
vivo studies (Table 2; Fig. 4a). In our previous studies, the
68Ga-chloride uptake to healthy rat pancreas was low (SUV
ab
d c
e
Fig. 4. a Tumor-to-blood, b tumor-to-liver, c tumor-to-lung, d tumor-to-muscle, and e tumor-to-skin ratios calculated from the
ex vivo measurements of
68Ga-chloride and FDG at 90 min after injection in tumor bearing athymic rats. *PG0.05; ***PG0.005.
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compared to the muscle, both
68Ga-chloride and FDG had
ratio ≥4 (Table 2; Fig. 4d). However, there was a great
variation in FDG accumulation in tumor xenografts between
animals. We used skin as another background tissue because
tumor cells were subcutaneously transplanted. In general, the
determination of true skin radioactivity is difficult, since hair
and subcutaneous fat may interfere with the results if not
carefully removed from the skin sample. Tumor-to-lung and
tumor-to-liver ratios are valuable when evaluating the
potential of a new imaging agent to differentiate tumors/
metastases from these tissues. Pancreatic cancer cells easily
send metastases, in particular, to the liver after surgical
operation [14], and many cancers, like breast cancer, are
Fig. 5. Representative digital autoradiographs of BxPC-3 tumor cryosections and corresponding hematoxylin and eosin
stainings. a
68Ga-chloride autoradiography at 90 min postinjection (p.i.) and b the HE-staining of the same section. c FDG
autoradiography at 90 min p.i. and d the corresponding HE staining. The dark blue represents the lowest and hot red the
highest amount of radioactivity.
Fig. 6. Hematoxylin and eosin stained paraffin sections of BxPC-3 tumor. a Tumor tissue is viable and without major necrotic
areas. Stroma is marked with an arrow. Bar=100μm. b BxPC-3 pancreatic adenocarcinoma cells form follicular structures
(arrows). Bar=50μm.
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tracers, FDG seems to be clearly superior to differentiate
tumors from the normal liver tissue (Table 2; Fig. 4b). FDG
seems the best in visualizing tumors in the lungs also.
Identification of tumors with
68Ga-chloride in the abdominal
area might be challenging due to high blood pool and liver
radioactivity, although use of magnetic resonance imaging
(MRI) or CT as an anatomical reference to PET might help.
Despite technological advances, PET is characterized by a
relatively low spatial resolution. In this work, we used clinical
PET devices (GE Advance and Siemens HRRT) for the
imaging of rat because at the time of the study, we did not
have access to a dedicated small animal PET scanner. The
animalwasplacedinthecenterofthescannergantrygivingthe
highest possible spatial resolution, i.e., 4.8 mm with GE
Advance and 2.7 mm with Siemens HRRT. Unfortunately, the
structures we were aiming at were quite small (tumor diameter
approximately 10 mm), which might result in partial-volume
effect (PVE) and possibly invalidate the in vivo quantitative
PET data. PVE means that the apparent pixel values in PET
images are influenced by the surrounding high pixel values
[18]. In the present study, the central 200-mm-diameter
transaxial field of view was reconstructed using OS-EM
algorithm [19]. Using the 128×128 matrix, this leads to the
pixel size of 1.56×1.56 mm, which is approximately one third
(GE Advance) or half (Siemens HRRT) of the image
resolution. Boellaard et al. have obtained superior image
quality by using OS-EM reconstruction instead of filtered
back-projection, resulting in lower PVE [20]. In theory, PVE
correction is possible if high-resolution structural imaging,
such as magnetic resonance imaging, can be coupled with the
information of the scanner resolution. However, lack of
anatomic MRI of the rats prevented PVE correction in this
study. To minimize the PVE, we used the average radioactive
concentration within the ROI (kiloBecquerels per milliliter).
The majority of positron-emitting radionuclides are pro-
duced by expensive accelerators requiring qualified personnel.
68Ga offers a cyclotron-independent, convenient, and low-cost
access to PET radiopharmaceuticals.
68Ga is readily available
by elution from
68Ge/
68Ga generator possessing 1–2y e a r sl i f e
span depending on uploaded
68Ge radioactivity. Furthermore,
68Ga has convenient characteristics for PET detection: β+
decay 89%, Eβ+max 1.9 MeV, and T1/2 68 min. It has been
shown that the clinical image qualities of
68Ga-tracers and
18F-
tracers (β+decay 97%, Eβ+max 0.64 MeV, T1/2 110 min) are
not necessarily very much different from each other [21].
Although the half-life of
68Ga is shorter compared to that of
18F, the significant advantage for
18F-tracers is the lower
radiation dose due to their lower positron energy. The
68Ge/
68Ga generator supplied by Cyclotron Co., which was used in
this study, contains
68Ge attached to a column of an inorganic
matrix-based titanium dioxide (TiO2). Several research groups
that are currently using this generator type have reported that
the
68Ge breakthrough is G0.01%, and concentration of other
metalions(Zn
2+,Al
3+,Ge
4+,Ti
4+,C u
2+)isG50nMinthe
68Ga-
eluate [3, 22–24].
When
68Ga is eluted from
68Ge/
68Ga generator with 0.1 M
HCl, it is in the form of
68GaCl3. At least some of the
68Ga is
hydrolyzed after neutralization with NaOH in situ or after
administration in vivo. In general, in aqueous solution,
68Ga is
intheformofasolubleanioncalledgallate, 68Ga OH ðÞ 4
 ,an d/
or insoluble neutral hydroxide colloids,
68Ga(OH)3,d e p e n d i n g
on pH and the concentration of
68Ga [24]. The
68Ga radio-
activity can migrate in the blood circulation as free
68Ga
3+ or
68Ga
3+ bound to transferrin, ferritin, or lactoferrin after rapid
intravenous administration to the vascular system.
67Ga is
injected as citrate for SPECT imaging. Since the citrate is only
aw e a kc h e l a t o rin vivo,
67Ga
3+ cation is rapidly released,
hydrolyzed, and/or bound to transferrin and other plasma
proteins. Because the citrate is able to prevent precipitation of
67Ga(OH)3, it is assumed that only a soluble 67Ga OH ðÞ 4
  is
formed in vivo. The use of
67Ga-citrate has been characterized
by its slow accumulation in tumors, which makes the imaging
of tumors by SPECT possible only after several hours, even
Fig. 7. Representative digital autographs and immunohistological stainings of BxPC-3 tumor cryosections. a
68Ga-chloride
autoradiography, b macrophage staining with CD68 antibody, and c magnification (×120) of the same section show rather
uniform distribution of the radioactivity and macrophages, respectively. The CD68 positive staining is strong also in the stroma.
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68Ga-chloride for PET, we
observed rapid localization of radioactivity in the target. The
form of
68Ga, i.e., the ratio of
68Ga-gallate and
68Ga-hydroxide
colloids, was not studied in this study.
The uptake mechanisms of radiogallium into tumors are
not fully understood, and a wide variety of factors are
involved. It is known that Ga
3+ behaves in vivo similarly to
Fe
3+ by binding to transferrin and using the same trans-
porters [25]. Gallium seems to concentrate in tissues having
high concentration of transferrin or transferrin receptors,
lactoferrin, or ferritin. All nucleated cells of the body express
transferrin receptors at different concentrations. Malignant
cells generally express high levels of transferrin receptors
because they divide and require iron for DNA synthesis.
However, there is some evidence that Ga can also enter
tumor cells by transferrin-independent mechanisms. This
may be due to a very small soluble gallate ion, Ga OH ðÞ 4
 ,
or a neutral insoluble, Ga(OH)3, both hydrolysis products of
Ga [25]. In this study,
68Ga radioactivity seemed to be taken
up mostly by viable cancer cell islets according to
68Ga
autoradiography and HE staining (Fig. 5). The comparison
of autoradiography and CD68 immunohistochemical stain-
ing (Fig. 7) suggests that the uptake might also be a result of
macrophage phagocytosis. The resolution of autoradiogra-
phy is not high enough to show the radioactivity uptake of
individual cells, but it rather shows the accumulation in
certain tissue areas, like tumor cell islets. It is possible that
the
68Ga radioactivity is taken up by both tumor cells and
infiltrating macrophages. Indeed, accumulation of Ga in
macrophages, leukocytes, and bacteria has been reported
[26, 27].
Fast tumor uptake of
68Ga-chloride would facilitate PET
imaging as soon as 2 h after injection vs. long-lasting study
procedure with
67Ga-citrate in SPECT imaging, although the
slow blood clearance of
68Ga-chloride suggests for a later
time point. At 2 h after injection, the high blood pool
radioactivity may contribute to tumor uptake as well.
Conclusions
68Ga-chloride and FDG PET imaging were able to delineate
subcutaneously implanted human pancreatic adenocarci-
noma xenografts in rats. The tumor uptake of FDG was
clearly superior, but there was great variation between the
animals.
68Ga-chloride showed fast tumor uptake, high
blood pool radioactivity, and low urinary excretion. Advanta-
geously,
68Ga-chloride is readily available from a generator
system and produces good PET image quality. However,
further studies are needed to clarify the value of
68Ga-chloride
for PET imaging of tumors.
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